Polymyxin B

Polymyxin B is a polypeptide antibiotic that has gained significant importance in equine medicine primarily for its unique ability to bind and neutralize bacterial endotoxins, making it a critical therapy for horses with endotoxemia. This medication belongs to the polymyxin class of antibiotics, which are among the oldest antimicrobial agents still in clinical use. While polymyxin B has direct antibacterial activity against gram-negative bacteria, its systemic use for this purpose is limited by nephrotoxicity and neurotoxicity concerns. In horses, the drug's value lies predominantly in its application for treating endotoxemia and for topical or ophthalmic use where systemic absorption is minimal.

The mechanism of action of polymyxin B involves interaction with the lipopolysaccharide component of gram-negative bacterial cell walls. The drug binds to lipid A, the toxic component of bacterial lipopolysaccharide (endotoxin), causing disruption of the cell membrane and cell death. This same binding property is what makes polymyxin B valuable for treating endotoxemia, as the drug binds to and neutralizes circulating endotoxin in the bloodstream. At typical doses used for endotoxin binding in horses, the antibacterial effect is secondary to the anti-endotoxin activity, though both contribute to clinical benefit in appropriate patients.

Polymyxin B is available in several formulations relevant to equine use. Injectable polymyxin B sulfate is used intravenously for treating endotoxemia in critically ill horses. Ophthalmic preparations, often combined with other antibiotics such as neomycin and bacitracin, are commonly used for treating bacterial eye infections. Topical formulations may be used for wound care, though other antibiotics are often preferred for this application. The drug is not absorbed from the gastrointestinal tract and is therefore not useful for oral administration.

The use of systemic polymyxin B in horses requires careful attention to dosing and monitoring due to the potential for nephrotoxicity and neurotoxicity. However, at the doses typically used for endotoxin binding in horses, which are lower than traditional antibacterial doses, the risk of toxicity is reduced. Ophthalmic and topical applications carry minimal systemic risk. Veterinary supervision is essential when using polymyxin B, particularly for systemic treatment of endotoxemia where the patient is already critically ill and careful monitoring of kidney function and hydration status is imperative.

The primary systemic indication for polymyxin B in horses is the treatment of endotoxemia, a life-threatening condition in which bacterial lipopolysaccharide enters the bloodstream and triggers a severe inflammatory response. Endotoxemia commonly occurs in horses with gastrointestinal disease, particularly colic and colitis, but can also result from any condition causing bacterial translocation from the gut or from gram-negative infections at other sites. The clinical signs of endotoxemia include fever followed by hypothermia, tachycardia, injected or cyanotic mucous membranes, delayed capillary refill time, and signs of shock. Polymyxin B helps neutralize circulating endotoxin and may improve outcomes in these critically ill patients.

The anti-endotoxin effects of polymyxin B are particularly valuable in horses because these animals are exquisitely sensitive to endotoxin compared to other species. Even relatively small amounts of endotoxin can trigger significant clinical signs in horses, and the development of laminitis as a sequel to endotoxemia is a devastating complication unique to equines. By binding and neutralizing endotoxin, polymyxin B may reduce the inflammatory cascade that leads to these complications. The drug is typically used as part of comprehensive intensive care for horses with endotoxemia, alongside fluid therapy, anti-inflammatory medications, and treatment of the underlying cause.

Ophthalmic infections represent another important indication for polymyxin B in horses. The drug is effective against many gram-negative bacteria that can cause conjunctivitis, keratitis, and corneal ulcers. Polymyxin B is frequently formulated in combination with other antibiotics such as neomycin, bacitracin, or gramicidin to provide broader coverage against both gram-positive and gram-negative organisms. These combination ophthalmic preparations are commonly used for treating bacterial eye infections in horses and are generally well-tolerated with minimal systemic absorption when applied topically to the eye.

Topical wound treatment is an additional application for polymyxin B in equine medicine, though other antibiotics may be preferred depending on the specific clinical situation. The drug's activity against gram-negative bacteria makes it useful for wounds contaminated with environmental organisms. Polymyxin B is often included in triple antibiotic ointments along with neomycin and bacitracin, providing broad-spectrum coverage for preventing and treating wound infections. These preparations are particularly useful for minor cuts, abrasions, and superficial wounds.

In cases of multidrug-resistant gram-negative bacterial infections, polymyxin B may be considered as a last-resort systemic antibiotic when other options have failed. This use is analogous to the drug's increasing application in human medicine against resistant organisms such as multidrug-resistant Pseudomonas aeruginosa and Acinetobacter species. However, due to nephrotoxicity concerns, this application in horses is reserved for exceptional circumstances where the infection is life-threatening and no safer alternatives are available or effective.

The dosing of polymyxin B in horses varies significantly depending on the indication being treated, with substantially different approaches for anti-endotoxin therapy versus antibacterial treatment. For endotoxemia, the drug is typically administered at doses designed to bind and neutralize circulating endotoxin rather than to achieve bactericidal blood levels. These anti-endotoxin doses are considerably lower than traditional antibacterial doses, which helps reduce the risk of nephrotoxicity. The veterinarian will determine the appropriate dose based on the specific clinical situation, the horse's weight, and the severity of endotoxemia.

For the treatment of endotoxemia in horses, polymyxin B sulfate is typically administered intravenously at doses of approximately 1,000 to 6,000 units per kilogram of body weight. This dosing range represents the anti-endotoxin application and is lower than doses that would be required for systemic antibacterial effect. The drug is usually diluted in intravenous fluids and administered slowly over 30 to 60 minutes to minimize adverse reactions. Repeat dosing may be given every eight to twelve hours depending on the clinical response and the underlying condition being treated. Treatment duration is determined by the resolution of endotoxemia signs and the course of the underlying disease.

Accurate weight determination is essential for calculating polymyxin B doses, as both underdosing and overdosing carry significant risks. A livestock scale provides the most accurate weight measurement, though a properly used weight tape can provide an estimate in field situations. Because horses receiving polymyxin B for endotoxemia are typically hospitalized in critical care settings where scales are available, accurate weighing should be standard practice. The relatively narrow therapeutic index of polymyxin B makes precise dosing more important than with many other medications.

Ophthalmic administration of polymyxin B follows different guidelines appropriate for topical eye medications. Combination ophthalmic preparations containing polymyxin B are typically applied to the affected eye every four to eight hours, depending on the severity of infection and the specific product being used. The horse's head should be stabilized during application, and care taken to avoid contaminating the applicator tip. The veterinarian will prescribe the appropriate frequency and duration of treatment based on the type and severity of eye infection.

If a dose of intravenous polymyxin B is missed or delayed in a hospitalized horse, the veterinary team should be notified to determine how to proceed. For outpatient ophthalmic treatment, missed doses should be given as soon as remembered, with subsequent doses adjusted appropriately. Doubling doses should never be done to compensate for missed doses. Completing the full prescribed treatment course is important for both systemic and ophthalmic applications to ensure adequate treatment of the underlying condition.

Monitoring during polymyxin B therapy is essential, particularly for systemic administration. Kidney function should be assessed before treatment and monitored throughout therapy, as nephrotoxicity is a significant concern. Hydration status must be maintained, and concurrent nephrotoxic medications should be avoided when possible. Clinical response to anti-endotoxin therapy should be evaluated regularly, with improvement in vital signs and reduction in signs of shock indicating therapeutic benefit.

Polymyxin B has significant potential for serious adverse effects, particularly nephrotoxicity and neurotoxicity, which have historically limited its systemic use in both human and veterinary medicine. Understanding these risks is essential for appropriate patient selection and monitoring during therapy. However, it is important to note that the anti-endotoxin doses used in horses are typically lower than traditional antibacterial doses, which may reduce but not eliminate the risk of toxicity. Ophthalmic and topical preparations carry minimal systemic risk when used as directed.

Nephrotoxicity is the most significant concern with systemic polymyxin B administration. The drug can cause acute kidney injury through direct tubular toxicity, leading to decreased urine output, elevated blood urea nitrogen and creatinine levels, and potentially acute renal failure. Risk factors for nephrotoxicity include dehydration, concurrent use of other nephrotoxic drugs, pre-existing kidney disease, and higher doses or prolonged therapy. Horses receiving polymyxin B should have renal function monitored, and adequate hydration is essential to reduce nephrotoxic risk. Any decrease in urine production or evidence of kidney dysfunction should prompt immediate veterinary evaluation.

Neurotoxicity represents another potential adverse effect of polymyxin B, though it is less commonly observed at the lower anti-endotoxin doses used in horses. Signs of neuromuscular toxicity may include weakness, respiratory depression due to neuromuscular blockade, and other neurological abnormalities. These effects are related to the drug's ability to interfere with neuromuscular transmission. Concurrent use of other drugs with neuromuscular blocking properties may increase this risk. If signs of neurotoxicity develop, discontinuation of the drug is necessary.

Infusion-related reactions may occur during intravenous administration of polymyxin B. Rapid infusion can cause histamine release, potentially leading to flushing, hypotension, and bronchospasm. These reactions can be minimized by diluting the drug appropriately and administering it slowly over 30 to 60 minutes or longer. Pre-treatment with antihistamines may be considered in some cases. Monitoring vital signs during infusion allows early detection of any adverse reactions.

Ophthalmic use of polymyxin B preparations is generally well-tolerated locally, though some horses may experience transient stinging or irritation upon application. Allergic reactions to ophthalmic preparations are possible but uncommon. Signs of ocular allergy may include increased redness, swelling, itching, or discharge that worsens rather than improves with treatment. If allergic reactions are suspected, the medication should be discontinued and the veterinarian notified. Systemic absorption from ophthalmic application is minimal, making systemic side effects unlikely with this route of administration.

Polymyxin B should not be used in horses with known hypersensitivity or previous allergic reactions to polymyxin B or other polymyxin antibiotics including colistin (polymyxin E). Horses that have experienced adverse reactions to these drugs in the past should receive alternative therapy. Before initiating polymyxin B treatment, owners should inform the veterinarian of any previous medications their horse has received and any reactions that occurred. Cross-reactivity between polymyxin B and colistin should be assumed.

Pre-existing kidney disease represents a significant contraindication for systemic polymyxin B use due to the drug's nephrotoxic potential. Horses with elevated creatinine or blood urea nitrogen levels, decreased urine production, or any other evidence of renal compromise should not receive systemic polymyxin B unless the potential benefits clearly outweigh the substantial risks and no safer alternatives exist. In such cases, extremely careful monitoring and possible dose adjustment would be necessary. The veterinarian must evaluate kidney function before initiating therapy.

Dehydration is a relative contraindication for polymyxin B administration, as hypovolemia significantly increases the risk of nephrotoxicity. Horses should be adequately hydrated before receiving systemic polymyxin B, and fluid therapy should be maintained throughout treatment. Since horses receiving polymyxin B for endotoxemia are often hypovolemic as part of their disease process, aggressive fluid resuscitation is a critical component of care that must be addressed alongside anti-endotoxin therapy. Monitoring urine output helps ensure adequate hydration is maintained.

The concurrent use of other nephrotoxic medications should be avoided when possible in horses receiving systemic polymyxin B. Aminoglycoside antibiotics such as gentamicin and amikacin pose particular concerns, as their combined use with polymyxin B significantly increases the risk of kidney damage. Other potentially nephrotoxic drugs include certain non-steroidal anti-inflammatory drugs and some diuretics. If concurrent nephrotoxic therapy cannot be avoided, enhanced monitoring of kidney function is mandatory.

Polymyxin B is a prohibited substance under equine competition regulations including those of the FEI, USEF, and racing commissions. Performance horses receiving systemic polymyxin B must be withdrawn from competition for an appropriate period. Since horses receiving polymyxin B for endotoxemia are typically critically ill, competition considerations are usually secondary, but documentation of treatment is essential for future regulatory compliance. Ophthalmic preparations may also have withdrawal time implications for competition horses.

The concurrent use of polymyxin B with other nephrotoxic medications presents the most significant drug interaction concern and should be avoided when possible. Aminoglycoside antibiotics including gentamicin, amikacin, and neomycin are particularly concerning when combined with polymyxin B, as both drug classes can cause kidney damage through similar mechanisms. The combined nephrotoxic effect may be additive or synergistic, substantially increasing the risk of acute kidney injury. If such combinations cannot be avoided due to the severity of infection, intensive monitoring of renal function is mandatory.

Non-steroidal anti-inflammatory drugs may contribute to nephrotoxicity risk when used with polymyxin B, particularly in horses that are dehydrated or have compromised renal perfusion. NSAIDs are commonly used in horses with endotoxemia for their anti-inflammatory and analgesic effects, creating a clinical situation where careful attention to hydration and renal function is essential. The veterinarian must weigh the benefits of NSAID therapy against the potential for compounding nephrotoxic effects and may adjust NSAID selection or dosing accordingly.

Polymyxin B can enhance the effects of neuromuscular blocking agents and drugs with neuromuscular blocking properties. This interaction may be relevant if anesthesia is required for surgical treatment of the underlying condition causing endotoxemia. Anesthetists should be informed if the horse has received polymyxin B, as the drug may prolong neuromuscular blockade and affect recovery from anesthesia. Other medications with potential neuromuscular effects should also be used cautiously in horses receiving polymyxin B.

Drug interactions affecting competition testing may be relevant for horses receiving ophthalmic polymyxin B preparations. While the systemic absorption from ophthalmic use is minimal, horses in competition must comply with all applicable regulations regarding prohibited substances. The presence of polymyxin B or concurrent medications in test samples could raise regulatory issues. Horse owners should discuss competition schedules with their veterinarian when any medications are being considered.

The binding of polymyxin B to endotoxin represents a beneficial interaction that is the basis for its therapeutic use in endotoxemia. This binding is not affected by most other medications, though the clinical response to anti-endotoxin therapy depends on many factors including treatment of the underlying cause, fluid therapy, and supportive care. The anti-endotoxin effect of polymyxin B should be considered one component of comprehensive treatment rather than a standalone therapy.

Monitoring during polymyxin B therapy is essential, with particular attention to kidney function for horses receiving systemic treatment. Baseline assessment of renal parameters including blood urea nitrogen, creatinine, and urine specific gravity should be obtained before initiating therapy when possible. Serial monitoring of these parameters during treatment allows early detection of nephrotoxicity. Urine output should be closely monitored in hospitalized horses, with decreased production potentially indicating developing kidney injury. Any deterioration in renal function should prompt reevaluation of the treatment approach.

Adequate hydration must be maintained throughout polymyxin B therapy to minimize nephrotoxic risk. Horses receiving the drug for endotoxemia often require aggressive intravenous fluid therapy as part of their overall treatment, and this fluid support also helps protect the kidneys. Monitoring hydration status through physical examination, urine output, and laboratory parameters is essential. If hydration cannot be maintained at adequate levels, the risk-benefit ratio of continuing polymyxin B therapy should be reassessed.

Polymyxin B is classified as a prohibited substance under equine competition regulatory frameworks including the FEI, USEF, and racing commissions. Performance horses receiving systemic polymyxin B must be withdrawn from competition until appropriate withdrawal times have passed. Since horses receiving polymyxin B for endotoxemia are typically critically ill, immediate competition considerations are usually not the primary concern, but documentation of all treatment is essential for future regulatory compliance. Ophthalmic preparations may also have detection time implications.

Special populations of horses require additional precautions. Foals receiving polymyxin B, whether for endotoxemia or other indications, may have different pharmacokinetic parameters than adult horses and may be more susceptible to toxicity. Geriatric horses and those with any degree of pre-existing renal compromise are at increased risk for nephrotoxicity. Pregnant mares should receive polymyxin B only when the benefits clearly outweigh the potential risks, as the effects on the developing foal are not well characterized.

The clinical context of polymyxin B use deserves emphasis. Horses receiving this drug for endotoxemia are critically ill with a serious, potentially life-threatening condition. The risks of nephrotoxicity must be weighed against the substantial risks of untreated or inadequately treated endotoxemia, including the development of laminitis and multi-organ failure. In appropriate cases, the benefits of polymyxin B therapy outweigh the risks, but this determination must be made by a veterinarian experienced in equine critical care with full assessment of the individual patient.

Proper storage of polymyxin B products is essential for maintaining medication potency and safety. Injectable polymyxin B sulfate should be stored according to the manufacturer's directions, typically at controlled room temperature or under refrigeration depending on the specific product. Reconstituted injectable solutions have limited stability and should be used promptly or refrigerated and used within the timeframe specified on the product labeling. Expired or degraded polymyxin B should not be used, as decreased potency could result in therapeutic failure while degradation products could increase toxicity risk.

Ophthalmic preparations containing polymyxin B should be stored according to their specific labeling instructions, typically at room temperature protected from light. Once opened, ophthalmic products have limited stability and should be discarded after the timeframe specified on the label, typically within 30 days for multi-dose containers. Contamination of ophthalmic preparations can occur with repeated use, potentially introducing bacteria into an already infected eye, so proper technique during application is essential. The applicator tip should never touch the eye surface or other contaminating surfaces.

Safe handling of polymyxin B focuses primarily on avoiding accidental injection or ingestion. While the drug is not absorbed orally, injectable preparations require standard precautions for handling injectable medications. Skin contact is not a significant concern, though hand washing after handling any medication is good practice. The drug should be kept out of reach of children and properly disposed of when no longer needed or expired.

Disposal of unused or expired polymyxin B should follow appropriate guidelines for pharmaceutical waste. Injectable solutions should not be poured down drains. Returning unused medication to a veterinarian for proper disposal is preferred. If direct return is not possible, mixing the medication with an undesirable substance, placing in a sealed container, and disposing with household trash is an alternative. Used syringes and needles should be placed in appropriate sharps containers.

In barn environments where polymyxin B ophthalmic preparations are being used for outpatient treatment, the medication should be kept in a clean, easily accessible location to facilitate proper treatment administration. Protection from extreme temperatures and contamination is important. A designated area for medication storage separate from feed and tack helps maintain organization and safety.

Draft horses and other large breeds receiving polymyxin B for endotoxemia require weight-appropriate dosing to ensure therapeutic effectiveness. These breeds often weigh 1,600 to 2,200 pounds or more, and accurate weight determination is essential for calculating anti-endotoxin doses. Since polymyxin B dosing for endotoxemia is already at the lower end of the dose range to minimize toxicity, underdosing in large horses could compromise therapeutic benefit. Hospitalized draft horses should be weighed accurately when possible. Larger horses also require larger fluid volumes for adequate hydration, which is essential for reducing nephrotoxicity risk.

Light horse breeds and Warmbloods respond to standard polymyxin B protocols when appropriately dosed for their body weight. Performance horses in these categories face competition regulation considerations, though horses sick enough to require polymyxin B for endotoxemia are typically too ill to compete regardless. Once recovered, appropriate documentation of treatment and adequate withdrawal time must be ensured before returning to competition. Thoroughbreds and other racing breeds fall under racing commission regulations that may have specific detection time information.

Ponies and miniature horses require careful dose calculation when receiving polymyxin B. These smaller equines may weigh 400 to 900 pounds for ponies and as little as 150 to 350 pounds for miniatures, and doses must be adjusted accordingly. Accurate weight determination is particularly important for these smaller patients to avoid both underdosing and overdosing. Smaller horses may also have different pharmacokinetic parameters, and monitoring for toxicity should be as vigilant as for larger horses.

No specific breed-related sensitivities to polymyxin B have been documented in horses. However, any breed can develop nephrotoxicity or other adverse effects when receiving systemic polymyxin B, making monitoring essential regardless of breed. Individual variation in drug handling exists within all breeds. Horses of any breed with pre-existing kidney disease or other risk factors for toxicity should be identified before treatment. The complete health history should be considered when planning polymyxin B therapy regardless of breed.

Colistin, also known as polymyxin E, is the most closely related antibiotic to polymyxin B and shares similar mechanisms of action, spectrum of activity, and toxicity profiles. Colistin has seen increased use in human medicine against multidrug-resistant gram-negative bacteria, and similar applications may be considered in veterinary patients under exceptional circumstances. The endotoxin-binding properties of colistin are comparable to polymyxin B, though polymyxin B is more commonly used for this indication in horses. Cross-reactivity between these drugs should be assumed for purposes of allergy history assessment.

For treating endotoxemia in horses, polymyxin B is often used alongside other therapies rather than as a standalone treatment. Flunixin meglumine is commonly administered for its anti-endotoxin effects through inhibition of cyclooxygenase enzymes, providing a different mechanism for managing the inflammatory response. Pentoxifylline may be used to improve blood flow and reduce inflammatory mediator production. Intravenous fluid therapy is essential for maintaining hydration and supporting circulation. These treatments work complementarily to address different aspects of the endotoxemic syndrome.

For gram-negative ocular infections, alternatives to polymyxin B-containing preparations include fluoroquinolone ophthalmic solutions such as ciprofloxacin or ofloxacin, which provide excellent gram-negative coverage with good corneal penetration. Gentamicin ophthalmic preparations offer another option with broad gram-negative activity. The choice between these options depends on the specific pathogen identified or suspected, the severity of infection, and patient factors. For many routine bacterial eye infections, combination polymyxin B preparations remain an effective and economical choice.

Systemic antibiotics for treating gram-negative infections in horses when polymyxin B's toxicity precludes its use include aminoglycosides, fluoroquinolones, and certain cephalosporins depending on the specific pathogen and infection site. Gentamicin and amikacin provide excellent gram-negative coverage but also carry nephrotoxicity risk. Enrofloxacin offers broad gram-negative activity with better safety profile but has its own concerns including cartilage effects in young animals. The specific alternative selected depends on culture and sensitivity results when available, the infection location, and patient factors including kidney function.